1. Prediction and identification of HLA-A*0201-restricted epitopes from cancer testis antigen CT23
   Xia Zeng et al, 2023, Human Vaccines & Immunotherapeutics CrossRef
2. Melanoma Antigen Family A (MAGE A) as Promising Biomarkers and Therapeutic Targets in Bladder Cancer
   Shiv Verma et al, 2024, Cancers CrossRef
3. The use of xenogenic testicular antigens for induction of antitumor reactions
   G. V. Seledtsova et al, 2024, Sib. onkol. ž. CrossRef
4. An Engineered M13 Filamentous Nanoparticle as an Antigen Carrier for a Malignant Melanoma Immunotherapeutic Strategy
   Nuša Brišar et al, 2024, Viruses CrossRef
5. Cancer testis antigens: Emerging therapeutic targets leveraging genomic instability in cancer
   Adviti Naik et al, 2024, Molecular Therapy: Oncology CrossRef
6. The dawn of a new Era: mRNA vaccines in colorectal cancer immunotherapy
   Jingjing Song et al, 2024, International Immunopharmacology CrossRef
7. Neoantigens and cancer-testis antigens as promising vaccine candidates for triple-negative breast cancer: Delivery strategies and clinical trials
   RamaRao Malla et al, 2024, Journal of Controlled Release CrossRef
8. Machine Learning for Early Discrimination Between Lung Cancer and Benign Nodules Using Routine Clinical and Laboratory Data
   Wei Wei et al, 2024, Ann Surg Oncol CrossRef
9. Proteomic Profiling of Pre- and Post-Surgery Saliva of Glioblastoma Patients: A Pilot Investigation
   Alexandra Muntiu et al, 2024, IJMS CrossRef
10. Antibodies Against Melanoma Antigens – Clinical and Therapeutical Markers
    Monica Neagu, 2025, JDR CrossRef